Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Pneumonia 1Lymphoma, Follicular 1Cytokine Release Syndrome 1COVID-19 1

Interventions

siltuximab 4tocilizumab 3fludarabine 3Cyclophosphamide 3fludarabine phosphate 2Interleukin 1 Receptor Antagonist Protein 2AP 1903 reagent 2talquetamab 1otelixizumab 1obinutuzumab 1lopinavir-ritonavir drug combination 1glofitamab 1axicabtagene ciloleucel 1Piperacillin, Tazobactam Drug Combination 1Oxygen Inhalation Therapy 1Oxaliplatin 1Neuropsychological Tests 1Metoprolol 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Lopinavir 1Leukapheresis 1Infliximab 1Hydroxychloroquine 1Heparin, Low-Molecular-Weight 1Gemcitabine 1Gelsolin 1Etanercept 1Dexamethasone 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × Gelsolin × Clear all
NCT04358406 2023-11-28

Rhu-pGSN for Severe Covid-19 Pneumonia

BioAegis Therapeutics Inc.

Phase 2 Completed
64 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, COVID-19, Lymphoma, Follicular, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡